Skip to main content

Menstruation Disturbances

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
1
TamoxifenPhase 41 trial
Active Trials
NCT02070692Completed56Est. Dec 2015
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Sedentary ControlN/A1 trial
Active Trials
NCT04938622Completed47Est. Apr 2005

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Oregon TherapeuticsTamoxifen
Human BioSciencesSedentary Control

Clinical Trials (2)

Total enrollment: 103 patients across 2 trials

Tamoxifen for the Treatment of Unfavorable Bleeding in Contraceptive Implant Users

Start: Feb 2014Est. completion: Dec 201556 patients
Phase 4Completed

Bioenergetics of Exercise-Induced Menstrual Disturbances

Start: May 2001Est. completion: Apr 200547 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.